AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination

By Reuters News

Oct 2 (Reuters) - AstraZeneca AZN.L and Daiichi Sankyo 4568.T have entered into a clinical collaboration with Summit Therapeutics SMMT.O to test their cancer drug, Datroway, in combination with Summit's ivonescimab across multiple tumour types, including lung and breast cancers.

  • The companies said on Friday that they intend to begin with a Phase III trial in first-line triple-negative breast cancer

  • The deal builds on AstraZeneca's $2 billion investment in Summit to collaborate on a series of studies testing their cancer treatments together

  • Under the agreement, each company will contribute its respective medicine and share trial costs, while retaining development and commercial rights to their own drugs

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.